1-Pyrrolidinecarboxylic Acid,2,2'-​([1,1'-Biphenyl]-4,4'-Diyldi-1H-​Imidazole-5,2-Diyl)Bis-,1,1'-Bis(1,1-​Dimethylethyl)Ester,(2S,2'S)-

Replacing the standard bis(oxazoline) ligand with (2S,2’S)-2,2’-([1,1’-biphenyl]-4,4’-diyldi-1H-imidazole-5,2-diyl)bis(pyrrolidine-1-carboxylic acid tert-butyl ester) in a copper(II)-catalysed Diels–Alder cycloaddition between cyclopentadiene and an N-acryloyl oxazolidinone shifts the endo/exo diastereomeric ratio beyond the prediction of frontier molecular orbital control. The C2-symmetric biphenyl backbone imposes a rigid chiral environment where the metal centre is chelated through the imidazole nitrogen atoms and the pyrrolidinecarboxylate carbonyl oxygen atoms. Pre-drying of the ligand powder is mandatory: vacuum treatment at 40 °C under 0.1 mbar for 4 h reduces adventitious moisture, verified by coulometric Karl Fischer titration per ASTM E1064 to remain below 50 ppm. Any water ingress above that threshold promotes μ-hydroxo-bridged copper oligomers that deactivate the catalyst. In a batch campaign operated within an ISO 14644-1 Class 8 production suite, a 200 L glass-lined reactor fitted with a pitched-blade turbine agitator and jacket temperature control is charged with anhydrous dichloromethane (water content <20 ppm via inline NIR) and the pre-formed copper(II) triflate–ligand complex. The ligand-to-copper stoichiometry is maintained at 1.05:1 to suppress free-copper-mediated racemic background reactions. Catalytic loading relative to the dienophile is typically 2.5–5.0 mol%. Reaction progress is tracked by offline chiral GC (Astec CHIRALDEX G-TA, 30 m × 0.25 mm) or HPLC on a Daicel Chiralpak IB column with n-hexane/2-propanol eluent. The downstream protocol includes an ammonium chloride quench, liquid-liquid separation, vacuum distillation, and isothermal crystallization from ethyl acetate/n-heptane. The resulting chiral cyclohexene intermediate, obtained with enantiomeric excess reaching ≥90 % e.e. in structurally analogous bis-imidazoline-pyrrolidine systems—published data for the exact (2S,2’S) diester are limited, necessitating pilot-scale validation—serves as a penultimate building block for prostaglandin endoperoxide analogues and vitamin D receptor agonists. All handling complies with ICH Q7 active pharmaceutical ingredient GMP and residual solvent limits of ICH Q3C.

What Limits Scale-Up Efficiency in the Asymmetric Cyclopropanation of Styrenes Using This Bis(imidazoline) Ligand System?

Industrial preparation of (1S,2S)-phenylcyclopropanecarboxylate esters—precursors to pyrethroid active substances such as cyfluthrin, tefluthrin and bifenthrin—by asymmetric cyclopropanation critically depends on the stability of the in-situ generated chiral copper(I) complex and the controlled addition kinetics of the diazoacetate reagent. The tert-butyl ester moieties of the pyrrolidinecarboxylic acid component provide steric shielding that retards catalyst dimerisation but necessitate rigorous oxygen exclusion during metalation. Inside a nitrogen-filled glovebox maintaining ISO 14644-1 Class 5 conditions, the (2S,2’S) diester is dissolved in anhydrous toluene (<30 ppm H₂O, confirmed by near-infrared spectroscopy) and combined with copper(I) tert-butoxide at a ligand-to-Cu molar ratio of exactly 1.0:1.0. Stirring for 30 min at 25 °C yields the active complex. When the catalyst loading relative to styrene is reduced to 0.5–1.0 mol%, controlled feeding of ethyl diazoacetate over 8–12 h through a calibrated diaphragm metering pump is mandatory to avert thermal decomposition. Jacket temperature is held at -5 °C, and the adiabatic safety margin is maintained at ΔT ≤ 20 °C below the onset temperature determined by differential scanning calorimetry per ASTM E537. Downstream work-up begins with an acetic acid quench, filtration through a 0.2 µm PTFE membrane to remove copper residues (target <1 ppm Cu in the final isolated ester, consistent with ICH Q3D), and fractional distillation under 0.05 mbar. Enantiomeric purity is quantified by chiral HPLC on a Chiralcel OJ-H column (250 × 4.6 mm, 5 μm particles) coupled with polarimetry. The chiral cyclopropane ester enters the synthesis stream of synthetic pyrethroids regulated under FAO/WHO JMPS specifications and, within the European Economic Area, restricted aromatic amine and metal release limits per REACH Annex XVII. A comparison of literature-derived performance markers for structurally analogous C2-symmetric bisimidazoline-pyrrolidine ligands is compiled in the following table; direct industrial metrics for the (2S,2’S)-biphenyl tert-butyl ester variant remain under disclosure embargo.

Henry Reaction Nitroaldol Process Windows and Catalyst Turnover Frequency

Chiral β-nitro alcohol intermediates required for the construction of norepinephrine reuptake inhibitor scaffolds and β-blocker side chains are accessed via a dinuclear zinc–ligand complex assembled from the (2S,2’S)-biphenyl bis-imidazoline-pyrrolidinecarboxylate diester. Under argon, the ligand is dissolved in anhydrous tetrahydrofuran and treated with 1.0 M diethylzinc in hexanes at 0 °C. After 15 min of ageing, the clear solution receives the benzaldehyde derivative and nitromethane sequentially. Catalyst loading operates efficiently within 5–10 mol% relative to the aldehyde, with a strict ligand:Zn ratio of 1:2 to avert bis-alkylated side products. For intermediates progressing into Phase II clinical manufacture, ICH M7 mutagenic impurity control is critical because the nitroalkane moiety itself can serve as a DNA-reactive alert structure; consequently, the downstream manufacturing stream integrates a continuous-flow hydrogenation reactor (10 g/h throughput, 5 wt% Raney Nickel slurry in ethanol) to eliminate the nitro group. Conversion of the NO₂ band at 1370 cm⁻¹ is monitored by inline Raman spectroscopy, ensuring less than 0.1 area% residual nitro compound before crystallisation of the chiral β-amino alcohol hydrochloride from isopropanol/methyl tert-butyl ether. Even though published performance data specific to the (2S,2’S)-biphenyl tert-butyl diester under Henry conditions are sparse, structurally homologous bis-imidazoline-pyrrolidine frameworks have returned enantiomeric excess values between 85–94 % (chiral HPLC with Chiralpak AD-RH, 250 × 4.6 mm).

When 1,5-Dicarbonyl Synthons Require Enantiocontrol via Imidazole-Pyrrolidine Coordination

The asymmetric Michael addition of diethyl malonate to cyclic enones, catalysed by a nickel(II)–bis(imidazoline-pyrrolidinecarboxylate) complex, provides access to chiral 1,5-dicarbonyl intermediates used in the total synthesis of cholesterol absorption inhibitors and sesquiterpene lactones. Catalyst pre-formation is executed in a 50 L Schleck-type vessel connected to a dual-manifold argon/vacuum line: the ligand is dissolved in anhydrous acetonitrile and combined with nickel(II) perchlorate hexahydrate in a 1:1 molar ratio, followed by addition of powdered 4 Å molecular sieves (activated at 300 °C under vacuum for 12 h). The ligand loading is reduced to 2 mol% when the reaction is run at 45 °C under an argon overpressure of 0.2 bar. The downstream purification involves filtration over a 0.5 µm sintered-glass frit to remove molecular sieves and precipitated nickel salts, aqueous bicarbonate washing, and flash chromatography on a Biotage® Isolera system loaded with 50 µm silica. Enantiomeric purity is verified by chiral HPLC on a Chiralpak IC column (150 × 4.6 mm, 3 µm) using supercritical CO₂/isopropanol. The resulting 1,5-dicarbonyl synthon is elaborated into statin-type API intermediates under full compliance with ICH Q11 development and manufacturing guidance, with genotoxic impurity tracking per ICH M7 and residual acetonitrile limits according to ICH Q3C Tables 2 and 3.

Asymmetric Sulfoxidation Protocols and the Role of the (2S,2’S)-Biphenyl Bis-imidazoline Framework

Proton pump inhibitor active substances such as esomeprazole magnesium, lansoprazole and pantoprazole sodium sesquihydrate rely on enantiopure sulfoxide intermediates that can be generated through a titanium/salicylaldehyde-derived ligand system. When the (2S,2’S) biphenyl-bridged bis-imidazoline-pyrrolidinecarboxylate diester is combined with titanium(IV) isopropoxide in dichloromethane at -20 °C, a chiral Lewis acid is formed that coordinates hydrogen peroxide and the prochiral thioether substrate. The formulation ratio of ligand to Ti(OiPr)₄ is tuned to 1.2:1, and the oxidant is added slowly as a 30 wt% aqueous H₂O₂ solution at a rate controlled to prevent exotherms exceeding 5 °C above the jacket set point. Catalyst loading relative to the thioether is typically 2.5–4.0 mol%. Post-reaction, the organic layer is washed with aqueous sodium sulfite to quench residual peroxide and with brine to remove titanium residues (target <10 µg/g Ti, aligned with ICH Q3D oral permitted daily exposure for parenteral applications). The sulfoxide is isolated by solvent swap into ethyl acetate and crystallization from methyl isobutyl ketone, achieving chiral purity exceeding 99.5 % e.e. as determined by direct chiral normal-phase HPLC on Chiralpak AS-H (250 × 4.6 mm, 5 µm). Manufacturing takes place in equipment compliant with ICH Q7 and EU GMP Part II, with dedicated cleaning validation to prevent cross-contamination of genotoxic sulfone by-product that forms above 2.5 mol% hydrogen peroxide excess.